Clinical Research Administration Fundamentals
This section serves as an entry point into clinical research administration for readers who need grounding in the field before working through its more specialized sub-topics. Clinical research administration sits at the intersection of medicine, regulatory law, data science, and institutional operations, and its practitioners are expected to understand how a trial moves from an initial research question through regulatory authorization, conduct, data collection, safety monitoring, and eventual reporting or submission. The broader field is shaped by the same reference points that recur throughout this cluster: the ICH (International Council for Harmonisation) guideline series, which spans everything from general trial design principles to safety reporting and quality standards for investigational products; national regulatory authorities such as the FDA and EMA, which authorize and inspect trial conduct; and professional and standards bodies such as SCDM, CDISC, and the ACRP/SOCRA certification framework, which govern data practices and workforce competency respectively. A newcomer encountering clinical research administration for the first time will run into all of these bodies in some form, which is why this fundamentals page exists as a map rather than a substitute for the more specific pages that follow. Topics covered here include the basic vocabulary of trial phases and roles, the lifecycle of a trial from protocol development to closeout, the general regulatory and ethical principles (such as informed consent and human subjects protection) that apply across virtually every trial, and an orientation to how the more specialized areas in this cluster - regulatory submissions, IMP manufacturing, data management, biostatistics, safety, and workforce credentialing - relate to one another as a trial progresses from planning to completion.
Guides
Cost-Minimisation Analysis and the Equivalence Assumption It Rests On
Cost-minimisation analysis compares only the costs of two interventions, valid only when their outcomes have already been shown equivalent. Here’s what the equivalence assumption requires, why it’s often weaker than claimed, and when a full cost-effectiveness analysis is needed instead.
Setting the LLOQ for a Bioanalytical Assay: Criteria and Justification
What sets a bioanalytical LLOQ apart from a generic LOQ calculation: the ICH M10 accuracy/precision criteria, how to bracket down to the true floor, and what a reviewer expects to see documented.
EU HTA Regulation & Joint Clinical Assessment
What the EU HTA Regulation’s Joint Clinical Assessment covers, its January 2025/2028/2030 phase-in by product category, JCA dossier requirements, and how it relates to national HTA and reimbursement decisions.
IVIVE: In Vitro-In Vivo Extrapolation of Hepatic Clearance
In vitro-in vivo extrapolation (IVIVE) scales intrinsic clearance from liver microsomes or hepatocytes into predicted hepatic clearance using MPPGL, hepatocellularity, and liver-weight scaling factors plus the well-stirred or parallel-tube liver model — with a well-documented tendency to under-predict clearance for some drug classes.
Time Trade-Off (TTO): Eliciting Health State Utility Values
How the time trade-off method elicits health state utility values for QALYs, how it compares to the standard gamble, and why value sets like EQ-5D are built from general-population TTO studies rather than re-elicited per study.
Allometric Scaling in Pharmacokinetics: Equation, Exponents, and Where It Fails
How allometric scaling extrapolates pharmacokinetic parameters like clearance across species using body weight, why the simple equation is well documented to fail for certain elimination pathways, and the correction methods (rule of exponents, MLP, brain weight) developed to address those failures.
Discounting Costs and Health Benefits in Cost-Effectiveness Analysis
How and why cost-effectiveness analysis discounts future costs and health benefits, the different reference-case rates used by NICE, the US Second Panel, CDA-AMC and the Netherlands, and the ongoing debate over differential discounting.
Markov Cohort Models in Cost-Effectiveness Analysis: States, Transitions, and the Cohort Trace
Markov cohort models move a hypothetical cohort through mutually exclusive health states over discrete cycles. This guide covers the core structure, the memoryless assumption and its limits, tunnel states, the cohort trace, and half-cycle correction, per ISPOR-SMDM good research practices.
NOAEL and First-in-Human Starting Dose
How the No Observed Adverse Effect Level from nonclinical toxicology studies is converted to a Human Equivalent Dose by allometric scaling, then to the Maximum Recommended Starting Dose using FDA’s default safety factor of 10 — the algorithm FDA’s 2005 guidance sets out for adult healthy-volunteer first-in-human trials.
Note to File in Clinical Research: When to Use One
What a Note to File can and cannot document in a clinical trial regulatory binder, and how auditors distinguish a legitimate one-off memo from a pattern of protocol deviations left uncorrected.
Protocol Deviation Log: Fields, Classification, and Trending
What a protocol deviation log should capture — classification, root cause, CAPA, IRB/sponsor notification — and how sites trend entries over time to catch systemic issues, not just isolated incidents.
Caco-2 Permeability Assay: Papp, TEER, and Efflux Ratio
What a Caco-2 monolayer Papp result actually measures, why TEER and Lucifer Yellow integrity checks come first, and how the efflux ratio catches P-glycoprotein-mediated transport a one-way permeability value would miss.
Hill Coefficient (nH) in Dose-Response and Binding Curves
The Hill coefficient (nH) sets how steeply a dose-response or binding curve rises. Here’s what nH=1, nH>1, and nH<1 actually indicate, and why the curve shape alone never proves true molecular cooperativity.
Incurred Sample Reanalysis (ISR) Under ICH M10
What ICH M10 requires for incurred sample reanalysis: why real study samples can behave differently from spiked QCs, the sampling percentages, and the ±20%/±30% acceptance criteria.
Budget Impact Analysis: What It Is and How It Differs From Cost-Effectiveness Analysis
Budget impact analysis projects the net financial effect of a new intervention on a payer’s budget over a defined time horizon — affordability, not value-for-money — and is why HTA bodies require it alongside a cost-effectiveness analysis.
Blood-to-Plasma Ratio (Rb): Converting Plasma Clearance to Blood Clearance
The blood-to-plasma concentration ratio (Rb) governs how a drug partitions between whole blood and plasma, and why plasma clearance must be converted to a blood basis before it can be used in a hepatic extraction ratio calculation.
Time-Kill Assays: Measuring Bactericidal Kinetics Over Time
Time-kill assays track viable colony counts over time against a fixed drug exposure, revealing bactericidal kinetics, the CLSI ≥3-log10 threshold, and concentration- vs. time-dependent killing patterns a single MIC value cannot show.
Minimum Inhibitory Concentration (MIC): How Broth Microdilution Determines It
Minimum inhibitory concentration (MIC) is the lowest antimicrobial concentration that stops visible growth. This guide covers how broth microdilution sets up the serial two-fold dilution, what counts as the MIC endpoint, how MIC relates to CLSI and EUCAST clinical breakpoints, and the most common sources of assay variability and error.
SF-36 (36-Item Short Form Health Survey) and Health-Related Quality of Life
How the SF-36 measures health-related quality of life across eight domains, how PCS/MCS summary scores are derived, and how SF-36 data is mapped to SF-6D or compared with EQ-5D to produce utility values for QALY-based health-economic models.
The Biopharmaceutics Classification System (BCS): Classes and Biowaivers
How the Biopharmaceutics Classification System (BCS) classifies drugs by solubility and permeability into four classes, and when the resulting BCS-based biowaiver lets a generic sponsor substitute in vitro dissolution testing for an in vivo bioequivalence study.
Toxicokinetics in Nonclinical Safety Studies
Toxicokinetics characterizes systemic exposure achieved within a nonclinical toxicity study, not therapeutic dosing, and is the basis for the exposure margins that support dose selection and a regulatory safety submission.
INESSS: Quebec’s Drug and Health Technology Assessment Institute
INESSS is Quebec’s own health technology assessment and drug-evaluation body, running a process parallel to (not covered by) CDA-AMC’s national reimbursement review.
pCPA (pan-Canadian Pharmaceutical Alliance): How Drug Price Negotiation Works
The pan-Canadian Pharmaceutical Alliance (pCPA) negotiates the confidential price manufacturers charge Canada’s public drug plans — the step between a positive CDA-AMC recommendation and a provincial formulary listing.
CDA-AMC (Canada’s Drug Agency): How Its Reimbursement Review Works
CDA-AMC (Canada’s Drug Agency, renamed from CADTH on May 1, 2024) runs the health technology assessment that decides whether an already Health Canada-approved drug is worth reimbursing — and why that recommendation alone doesn’t guarantee coverage.
The NICE Technology Appraisal Process: How Evidence Becomes NHS Guidance
How NICE turns clinical and cost-effectiveness evidence into a binding NHS recommendation: STA vs MTA, evidence review groups, the appraisal committee, and the QALY/ICER threshold decision.
NIHR Research Support Service (RSS): Free Help With Study Design and Funding Applications
What the NIHR Research Support Service (RSS) does, its 8 regional hubs, and how it differs from the delivery-focused NIHR Research Delivery Network (RDN).
NIHR Research Delivery Network (RDN): Structure and How to Get Study Support
What the NIHR Research Delivery Network (RDN, formerly the CRN) does, its 12 regional networks, and how study teams engage it for portfolio adoption and NHS support costs.
What Is Off-Label Drug Use?
Off-label drug use means prescribing an FDA-approved drug for a use, dose, or population outside its approved label. It is legal for physicians under the practice-of-medicine principle, but restricted for manufacturer promotion, and distinct from investigational (IND) and expanded-access drug use.
Building a Field Research Medical Kit for Site Visits and Data Collection
A practical guide to building a field research medical kit for off-site biospecimen collection, decentralized-trial home visits, community-based participatory research fieldwork, and mobile clinic work — covering personal/participant safety, specimen cold-chain and shipping-classification supplies, data-collection integrity, and kit sizing by visit type.
Virtual phone numbers for multi-country research studies
Why study teams need a number that is not a personal mobile, how local numbers lift participant answer rates, and what they cost across countries.
HIPAA-compliant form builders for clinical and research teams
Which HIPAA compliant form builder will actually sign a BAA, whether Google Forms qualifies, and the configuration mistakes that leak PHI regardless.
Clinical Trial Patient Recruitment Landing Pages: What Actually Converts Under IRB
Clinical trial patient recruitment fails when the study page is buried on the institutional site. What a dedicated, IRB-approved landing page changes.
Clinical Trial Claim Coding: Condition Code 30, Q0/Q1, and Value Code D4
How Condition Code 30, ICD-10 Z00.6, value code D4, and HCPCS modifiers Q0/Q1 actually go on a Medicare qualifying-clinical-trial claim, field by field, on institutional versus professional claim forms, with a worked example.
Medical Science Liaison: What the Role Is and How to Enter It
What a medical science liaison (MSL) does day to day, why the role is firewalled from sales, entry requirements, how a postdoc or clinical background translates, and the MSL career ladder.
IRB Protocol: Worked Example of a Full Submission
A complete, annotated, illustrative IRB protocol narrative — section by section — showing what a full submission looks like and why each part is written the way it is.
Clinical Research Management: Roles, Lifecycle, Systems, and Compliance
An orchestrating overview of clinical research management: who does what (PI, CRC, CRA, data manager), the trial lifecycle from feasibility to archiving, essential documents and systems (TMF, DoA log, CTMS, EDC), GCP and quality compliance, budgeting and coverage analysis, and the metrics that matter.
21 CFR: What Title 21 of the Code of Federal Regulations Covers
A routing guide to Title 21 of the Code of Federal Regulations: how CFR citations are structured, and which Part governs electronic records, informed consent, IRBs, GLP, INDs, NDAs, device studies, and device quality.
No-Show and Missed-Visit Billing Policy for Clinical Trial Participants: What Sponsors and Sites Can (and Can’t) Charge
A missed clinical trial visit raises three separate billing questions — claim billing to Medicare, a direct no-show fee to the participant, and sponsor cost responsibility under the CTA budget. This guide separates the three and covers what’s actually permissible in each.
Clinical Trial Charge Capture and Billing Reconciliation: Closing the Gap Between Coverage Analysis and Claims
How research billing offices confirm that a finished coverage-analysis billing grid actually reaches the claim correctly: charge routing, claims-editing markers, reconciliation cadence, and where double billing and missed revenue actually happen downstream of coverage analysis.
OIG Self-Disclosure Protocol for Clinical Research Billing Overpayments: When and How to Use It
When a clinical research billing overpayment is entangled with possible Anti-Kickback Statute exposure, HHS-OIG’s Health Care Fraud Self-Disclosure Protocol offers a reduced damages multiplier, lower minimum settlement amounts, and a presumption against a Corporate Integrity Agreement — but only for genuinely voluntary disclosures, and only for conduct within its scope.
Medicaid Coverage of Clinical Trial Routine Costs: The Clinical Treatment Act Explained
How the Clinical Treatment Act made routine-cost coverage for clinical trial participants a mandatory Medicaid benefit nationwide, and how it differs from Medicare NCD 310.1 and TRICARE coverage.
TRICARE Clinical Trial Coverage: DOD’s Final Rule and What Changed for Military Beneficiaries
DOD’s 2025 final rule (32 CFR 199) makes TRICARE’s clinical-trial routine-cost benefit permanent and general to NIH-sponsored Phase I-IV trials for severe, life-threatening, or rare conditions — replacing the earlier COVID-19-only provision. Here’s what changed and how it differs from Medicare’s NCD 310.1.
Stark Law and Clinical Research: How the Physician Self-Referral Exception Applies to Investigators
Stark Law’s physician self-referral rules reach clinical trial investigator compensation whenever a physician-investigator is paid by an entity that also furnishes Medicare-covered services. This guide covers what Stark prohibits, the compensation exceptions institutions actually use for investigator agreements, and how Stark differs from the Anti-Kickback Statute.
Hub-and-Spoke Clinical Trial Site Networks: Structure, Benefits, and Operational Considerations
A structural guide to hub-and-spoke clinical trial site networks: how the hub-spoke model is organized, why sponsors adopt it, key operational considerations (staffing, data consistency, monitoring, IRB oversight), and how it compares to fully decentralized trial designs.
Coverage with Evidence Development (CED): CMS’s Medicare Coverage Mechanism
How CMS’s Coverage with Evidence Development (CED) mechanism conditions Medicare payment on registry or clinical-study participation, and what it means for research administration and billing.
Category A vs. Category B IDE Studies: Medicare Coverage Differences
FDA assigns every Investigational Device Exemption (IDE) study a Category A (experimental) or Category B (nonexperimental/investigational) classification, and that classification — not the trial phase — decides whether Medicare will ever cover the device itself, not just routine care costs.
Advance Beneficiary Notice (ABN) in Clinical Trial Billing: When Medicare Won’t Cover Routine Costs
How the ABN (CMS-R-131) works inside clinical trial billing: when it legitimately applies to a routine-cost item, why it cannot be used for sponsor-owed research costs, the GA/GZ/GX/GY modifiers, and how to build ABN triggers into a coverage analysis.
Cayuse Research Suite: IRB, Grants, and Compliance Software Overview
A module-by-module overview of the Cayuse Research Suite: IRB (Human Ethics), pre-award and post-award grants modules, COI/IACUC/biosafety compliance tools, vivarium management, and technology transfer, sourced directly from cayuse.com.
OnCore CTMS Coverage Analysis: How S/R/Q Billing Designations Actually Get Set
How the S (standard of care), R (research), and Q (qualifying) billing designations get derived from Medicare coverage analysis and applied inside a CTMS billing grid built on the OnCore model.
OIG Exclusion List Screening for Clinical Research Staff and Investigators
Why sponsors, sites, and IRBs must screen principal investigators, sub-investigators, coordinators, and other trial staff against the HHS-OIG LEIE — what exclusion means, who counts as research staff, how often to check, and what to do if you get a match.
NCI’s Cancer Trials Support Unit (CTSU): How It Centralizes Billing and Regulatory Support
CTSU is the NCI service that centralizes regulatory documentation, IRB/CIRB reliance, and billing-compliance support for sites running NCTN, NCORP, and ETCTN cancer trials.
Clinical Trial Billing Compliance: A Beginner’s Checklist
A practical, step-by-step checklist introducing clinical trial billing compliance for newcomers: Medicare Coverage Analysis, the routine-cost vs. research-cost split under NCD 310.1, the billing grid, and the errors that create False Claims Act exposure.
Human Subjects Research: Definition Under 45 CFR 46.102
The Common Rule’s two-part regulatory test for human subjects research: the ‘research’ definition at 45 CFR 46.102(l) and the ‘human subject’ definition at 46.102(e), including intervention, interaction, and identifiable private information.
Clinical Trial Budget Negotiation: Strategy for Sites and Sponsors
How research sites, sponsors, and CROs negotiate clinical trial budgets: per-patient cost benchmarking, non-refundable startup costs, screen-failure cost coverage, and payment milestone structuring.
Clinical Trial Study Renewal, Closure, and Reopening Determinations
How IRB continuing review renews a study’s approval, what a formal closure determination requires (final report, record retention), and what reopening a closed study actually involves.
Clinical Trial Budget Example: A Line-Item Walkthrough
A worked, illustrative composite clinical trial budget showing how startup costs, per-patient/per-visit costs, and institutional overhead combine into a site budget.
Clinical Trial Patient Retention: Strategies, IRB Review, and Diversity in Completion
A guide to clinical trial patient retention as an operational and IRB-compliance topic: retention vs. recruitment, why attrition matters for power and data integrity, IRB review of retention communications and payments, withdrawal rights, LTFU tracking, and how differential attrition can erode enrollment diversity gains.
Medicare Coverage Analysis for Clinical Trials: The Complete Process
A step-by-step guide to Medicare Coverage Analysis (MCA): the billing-compliance process, required before trial activation, that maps every protocol item to Medicare, the sponsor, or the patient under CMS NCD 310.1.
Third-Party Person-Locating Services for Long-Term Follow-Up (LTFU) Data Collection
How and when clinical research teams use commercial person-locating services to maintain contact with participants during long-term follow-up (LTFU), including the IRB, informed-consent, and HIPAA considerations raised by FDA’s long-duration gene therapy LTFU expectations.
IRB Noncompliance & Unanticipated Problem Reporting: What Must Be Reported, By Whom, and On What Timeline
A practical breakdown of what US federal regulations actually require an IRB to report — unanticipated problems, serious or continuing noncompliance, and suspension/termination of approval — to institutional officials, OHRP, and FDA, and on what timeline.
False Claims Act Liability in Clinical Trial Billing
How the False Claims Act applies to clinical trial billing, distinct from grant-related FCA exposure: Medicare/sponsor double-billing, NCD 310.1 coverage analysis, real DOJ settlements, qui tam mechanics, and the Stark Law/Anti-Kickback Statute intersection.
Pharmaceutical CRO Industry: A Sector Overview
A sector-level overview of the pharmaceutical CRO industry: market structure and tiers, why sponsors outsource, typical service lines, and how sponsors select and govern a CRO relationship.
Medicare Coverage Determinations: NCD vs LCD Explained
National vs Local Coverage Determinations explained: who issues NCDs and LCDs, how NCD 310.1 governs Medicare coverage of routine clinical trial costs, and how the mechanism drives clinical trial billing compliance.
Clinical Trial Site Selection: How Sponsors and CROs Choose Sites
How sponsors and CROs identify, evaluate, and select clinical trial sites: feasibility questionnaires, prior enrollment performance, patient population access, PI experience, infrastructure, and competing-trial considerations.
Patient Engagement in Clinical Trials: What It Means and How It Works
How patient engagement shapes clinical trial design and conduct, the mechanisms behind it (patient advisory boards, PCORI’s Engagement Rubric, PRO input), and how it differs from a Community Advisory Board or an FDA Diversity Action Plan.
The Evolution of Clinical Trials: From Nuremberg to Decentralized Trials
How clinical trial ethics and methodology evolved from the Nuremberg Code through the Declaration of Helsinki, the Belmont Report, ICH GCP, and modern risk-based and decentralized trials — and why the lineage matters for research administrators today.
Clinical Trial Outsourcing: In-House vs. Full-Service CRO vs. FSP — A Sponsor’s Decision Framework
A sponsor-side decision framework for clinical trial outsourcing: in-house/hybrid management vs. full-service CRO vs. Functional Service Provider (FSP), and the cost, control, speed, and capability tradeoffs that drive the choice.
Study Start-Up in Clinical Trials: From Site Selection to First Patient In
Study start-up is the phase between protocol finalization and first patient enrolled: site selection, contract and budget negotiation, IRB/ethics approval, document collection, and the Site Initiation Visit. What it covers, typical timelines, and where it commonly stalls.
Clinical Trial Recruitment Companies: Vendor Types, Services, and How to Evaluate One
A guide to the clinical trial patient-recruitment vendor landscape — SMOs, creative agencies, screening-technology platforms, and EHR-matching companies — and the criteria sponsors and sites use to evaluate and select one.
Clinical Trial Feasibility Assessment: How Sponsors Decide a Protocol Can Be Run
What clinical trial feasibility assessment evaluates before site selection: eligible patient population, protocol complexity, standard-of-care alignment, competing trials, and regulatory pathway.
Durham-Humphrey Amendment of 1951: How the FDA Created the Prescription vs. OTC Drug Distinction
The 1951 Durham-Humphrey Amendment split U.S. drug law into prescription (legend) and OTC categories and is still the statutory basis for that distinction today.
Clinical Trial Patient Recruitment: Methods, Screening, and Enrollment
A practical guide to clinical trial patient recruitment: referral, registry, community, and digital recruitment channels, the IRB-approval requirement for advertising materials, screening and informed consent, screen-failure tracking, NIH diversity/inclusion requirements, and how recruitment shapes trial timeline and budget.
The Cost of Running a Clinical Trial: A Budgeting Guide for Research Administrators
A research-administration guide to budgeting a clinical trial: the cost categories to plan for (site fees, IRB fees, CTMS, monitoring, CRO fees, participant payments, indirect costs), why costs vary so much by phase and therapeutic area, and what published studies (Sertkaya/ASPE, Moore et al./JAMA, DiMasi et al./Tufts) actually report.
Is Your Study a Clinical Trial? The NIH Definition Explained
NIH defines a clinical trial by a four-question test, not by phase or product type. What the test asks, what it triggers (registration, GCP training, sIRB), how it differs from FDA’s and ICMJE’s definitions, and the confirmed 2026 BESH reclassification.
